[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345567-105":59,"doc-detail-345567-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","pan-cancer-analysis-and-experimental-validation-identify-cyp19a1-as-a-prognostic-biomarker-and-oncogenic-driver-associated-with-tumor-immune-microenvironment","Pan-cancer analysis and experimental validation identify CYP19A1 as a prognostic biomarker and oncogenic driver associated with tumor immune microenvironment","","CYP19A1 encodes aromatase, an enzyme critical for estrogen production, and is implicated in hormone-sensitive cancers; its function in gastrointestinal (GI) cancers remains uncertain. Pan-cancer bioinformatics using TCGA was integrated with transcriptomic, clinical, epigenetic, immune-infiltration, network, and regulatory analyses, followed by functional validation in mouse models of gastric and colon cancer and multiple human cancer cell lines. Higher CYP19A1 expression correlated with advanced GI stages and worse prognosis, linked to immunosuppressive microenvironment features and steroid-hormone and endocrine-resistance pathways. Functional assays showed CYP19A1 upregulation increased migration and invasion. Results support CYP19A1 as a prognostic biomarker and a therapeutic target, including aromatase inhibitors and immune-modulating strategies.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-analysis-and-experimental-validation-identify-cyp19a1-as-a-prognostic-biomarker-and-oncogenic-driver-associated-with-tumor-immune-microenvironment/345567/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-and-experimental-validation-identify-cyp19a1-as-a-prognostic-biomarker-and-oncogenic-driver-associated-with-tumor-immune-microenvironment/345567.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is CYP19A1 and why is it relevant to gastrointestinal cancers?","Question",{"text":112,"@type":113},"CYP19A1 encodes aromatase, a key enzyme in estrogen biosynthesis. Although its role is established in hormone-sensitive cancers, its impact on GI cancers and related mechanisms was not fully clear.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was CYP19A1 investigated in the study?",{"text":117,"@type":113},"The work combined pan-cancer bioinformatics analyses using TCGA with experimental validations. It assessed transcriptomic, clinical, epigenetic, immune infiltration data, functional networks, and regulatory mechanisms, then tested models and cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about CYP19A1 expression and patient outcomes?",{"text":121,"@type":113},"Higher CYP19A1 expression was observed in stomach, liver, and colon cancers and was associated with more advanced stages and poorer prognosis.",{"name":123,"@type":110,"acceptedAnswer":124},"What functional effects did CYP19A1 manipulation have?",{"text":125,"@type":113},"Higher CYP19A1 expression enhanced cancer cell migration and invasion, while lowering CYP19A1 produced the opposite effects, supporting a functional oncogenic contribution.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},345567,1790206733,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Lin et al. Discover Oncology (2026) 17:887 [https://doi.org/10.1007/s12672-026-04998-y](https://doi.org/10.1007/s12672-026-04998-y)  \nDiscover Oncology  \nRESEARCH Open Access  \nPan-cancer analysis and experimental validation identify CYP19A1 as a prognostic biomarker and oncogenic driver associated with tumor immune microenvironment  \nregulation in gastrointestinal cancers  \nZongrong Lin2†, Zhenyang Fu2†, Sicheng Chen3†, Haomin Xie2†, Yanqiu Pang1†, Ting Li4† and Hongcheng Chen1*  \n†Zongrong Lin, Zhenyang Fu, Sicheng Chen, Haomin Xie, Yanqiu Pang and Ting Li contributed equally to this work.  \n*Correspondence:  \nHongcheng Chen[chenhongcheng2022@126.com](chenhongcheng2022@126.com)[ ](chenhongcheng2022@126.com)1Department of Gastroenterology, Central People’s Hospital of Zhanjiang, No. 236 Yuanzhu Road, Chikan District, Zhanjiang 524000, Guangdong, China 2Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, The First Clinical Medical School of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou  \n510080, China  \n3Department of Cardiovascular Disease, Shantou Hospital of Traditional Chinese Medicine, Shantou 515000, China 4International Medical Services, Cancer Hospital of Shantou University Medical College, Shantou 515000, China  \nAbstract  \nBackground CYP19A1, which encodes the enzyme aromatase necessary for estrogen production, is known to be involved in hormone-sensitive cancers, but its role in gastrointestinal cancers is not completely clear.  \nMethods To examine CYP19A1 in gastrointestinal cancers, we carried out pan-cancer bioinformatics analyses using theTCGA dataset as the main source, combined with experimental validations. A systematic analysis was conducted on transcriptomic, clinical, epigenetic, immune infiltration data, functional networks, and regulatory mechanisms. Functional experiments were conducted using mouse models of gastric and colon cancer, as well as human cancer cell lines such as AGS, MKN45, SGC7901, HCT116, SW480, and LoVo.  \nResults Higher levels of CYP19A1 expression are found in stomach, liver, and colon cancers, which are associated with more advanced stages and poorer prognosis. The increase in its expression may be related to immune profiles specific to certain cancer types and might help create an immunosuppressive tumor microenvironment in gastrointestinal cancers, as shown by immune infiltration analysis. GO and KEGG enrichment analyses suggest that CYP19A1 is linked to pathways involved in steroid hormone synthesis, cancer-related signaling, and endocrine resistance, indicating its role in the progression of hormone-driven cancers. Functional tests indicated that higher CYP19A1 expression enhanced cancer cell migration and invasion, whereas lowering it produced the opposite outcome.  \nConclusions The combined computational and experimental findings identify CYP19A1 as a prognostic biomarker and a functional contributor to gastrointestinal cancers. The results support exploring CYP19A1-specific treatments, including aromatase inhibitors and immune-modulating tactics, in this cancer group with a considerable burden.  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use i","cbCait4gB4oktIoJ","https://ap.wps.com/l/cbCait4gB4oktIoJ","pdf",3907861,25,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is CYP19A1 and why is it relevant to gastrointestinal cancers?\",\"answer\":\"CYP19A1 encodes aromatase, a key enzyme in estrogen biosynthesis. Although its role is established in hormone-sensitive cancers, its impact on GI cancers and related mechanisms was not fully clear.\"},{\"question\":\"How was CYP19A1 investigated in the study?\",\"answer\":\"The work combined pan-cancer bioinformatics analyses using TCGA with experimental validations. It assessed transcriptomic, clinical, epigenetic, immune infiltration data, functional networks, and regulatory mechanisms, then tested models and cell lines.\"},{\"question\":\"What did the study find about CYP19A1 expression and patient outcomes?\",\"answer\":\"Higher CYP19A1 expression was observed in stomach, liver, and colon cancers and was associated with more advanced stages and poorer prognosis.\"},{\"question\":\"What functional effects did CYP19A1 manipulation have?\",\"answer\":\"Higher CYP19A1 expression enhanced cancer cell migration and invasion, while lowering CYP19A1 produced the opposite effects, supporting a functional oncogenic contribution.\"}]","Pan-cancer analysis and experimental validation identify CYP19A1 as a prognostic biomarker and oncogenic driver associated with tumor immune microenvironment | PDF",1790058103,63,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48b13ed1277b4e4f5aecb14bb30be7f2.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65496672201e19dfc49625b62fe63a3e.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87df2477f09c086d45c735c6a1f9af81.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4519c73708ee6db5c0988e5f493bc095.webp",980,1306]